Observational studyBMC ophthalmology2026
Assessment of corneal endothelial morphology in retinal vein occlusion.
Observational study in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate corneal endothelial morphology in patients with retinal vein occlusion (RVO) and to investigate the differential impact of ischemic versus non-ischemic status on endothelial cell integrity, while controlling for therapeutic interventions.
methodsThis prospective observational study enrolled 42 patients (84 eyes) with unilateral RVO. All participants were receiving intravitreal anti-VEGF therapy as part of their standard clinical care for retinal vein occlusion-related macular edema. Based on fundus fluorescein angiography findings, participants were stratified into ischemic (n = 21) and non-ischemic (n = 21) subgroups. Detailed endothelial assessment-including endothelial cell density (ECD), average cell area, coefficient of variation (CV), and hexagonality-was performed using non-contact specular microscopy. The fellow unaffected eyes served as internal controls to calculate intra-individual differences (delta analysis), thereby minimizing the impact of inter-subject variability. The study also assessed the potential confounding roles of intravitreal anti-VEGF injections and retinal laser photocoagulation.
resultsDirect intergroup comparison of absolute endothelial values showed no significant differences between ischemic and non-ischemic eyes (p > 0.05). However, intra-individual analysis revealed significant subclinical endothelial compromise specific to the ischemic phenotype. Ischemic RVO eyes demonstrated a significant reduction in ECD (p = 0.010), decreased analyzable cell count (p = 0.010), and increased average cell area (p = 0.002) compared to their healthy fellow eyes. Conversely, non-ischemic RVO eyes exhibited preserved endothelial structure comparable to fellow eyes, with no significant morphometric alterations. Importantly, the frequency of anti-VEGF injections did not differ significantly between the groups (p = 0.130), suggesting that the observed endothelial changes were ischemia-driven rather than treatment-induced.
conclusionCorneal endothelial alterations in RVO are predominantly ischemia driven, whereas non-ischemic eyes maintain structural integrity. This study highlights the importance of anterior segment monitoring in ischemic RVO and support the role of ischemic burden in subclinical endothelial compromise.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.